Bruno Vincenzi

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Daniele Santini, Bruno Vincenzi, Giordano Dicuonzo et al. · PubMed · 2003 · 356 citations

Medicine, Oncology, Pharmacology +17

Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Daniele Santini, Bruno Vincenzi, Giuseppe Avvisati et al. · PubMed · 2002 · 276 citations

Medicine, Oncology, Pharmacology +17

Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients

Cristina Raimondi, Angela Gradilone, Giuseppe Naso et al. · Breast Cancer Research and Treatment · 2011 · 268 citations

Medicine, Cell Biology, Oncology +17